Daily Brief Health Care: PANACRO (Hangzhou) Pharmaceutical Consulting, Shanghai Conant Optical, Medcaptain Medical Technology, Nexgel , HCW Biologics , SKG Health Technologies, Moderna , Novo Nordisk, Inspire Medical Systems Inc, IDEXX Laboratories and more

• Panacro (Hangzhou) Pharmaceutical Consulting Co., Ltd. is a clinical CRO based in Hangzhou, China, advancing clinical research through digital transformation. It provides clinical trial technical services to accelerate drug development.
• Proprietary digital infrastructure integrates CTMS, eTMF, and CTFS across the full project lifecycle. The company reported a gross profit margin of 38.9% in 2025.
• Net cash generated from operating activities was RMB46,583 thousand for the six months ended June 30, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• In 1H26, Shanghai Conant Optical (2276 HK) reported revenue rise of 8% YoY buoyed by growth across segments like multifunctional lens (up 12%) and customized lens (up 37%).
• In 1H26, the company kept up with its consistency of expanding its gross margins period after period, as margin expanded from 41% in 1H25 to 42.9% in 1H26.
• Shanghai Conant’s demand outlook, capacity expansion plans, R&D initiatives and margin strength offer a strong long term secular growth story.

• Medcaptain Medical Technology is a global medical device provider with a product portfolio across life support, minimally invasive intervention, and in vitro diagnostics, serving over 140 countries and regions.
• The company ranked first in China’s infusion workstation market from 2018 to 2025, reaching over 6,000 hospitals in China and 140 countries globally.
• FY2025 revenue was RMB1,619,152 thousand, and gross profit was RMB869,660 thousand. The company reported a net loss of RMB96,617 thousand in FY2024.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• NexGel, Inc. manufactures high water content hydrogels for various applications, serving as a contract manufacturer and marketing branded consumer products, recently acquiring Celularity Inc.’s BioNx portfolio.
• NexGel manufactures high water content hydrogels, specializing in custom gels using proprietary technologies. The company acquired Celularity Inc.’s BioNx portfolio on April 17, 2026, and operates two segments.
• NexGel reported a net loss of $4.5 million and used $2.7 million cash in operations for the six months ended June 30, 2026, with substantial doubt about its ability to.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for diseases promoted by chronic inflammation. It also commercializes proprietary compounds as reagents.
• HCW9302 showed preliminary clinical activity in Phase 1. HCW11-018b and HCW11-040 have Phase 1 trials planned for 2027. Founder Dr. Wong discovered Anktiva®.
• Material weaknesses were identified regarding long-lived assets and warrant modifications. Q1 2026 financial statements should not be relied upon due to an EPS calculation error.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• SKG’s 16.5% revenue growth in 2025 masks a fundamental shift toward lower-margin physical massagers and unprofitable smartwatches, exposing the company to severe margin compression as the gross margin dropped from 50.7% to 48.2% in early 2026.
• The company operates primarily as a discretionary consumer electronics player rather than a sticky medical-utility brand, with demand heavily dependent on high-cost marketing funnels (sales expenses rising to 23.6% of revenue) and seasonal gifting cycles rather than clinical necessity.
• Competitively, SKG is trapped between Breo’s high-end niche and a brand-licensing onslaught from Philips, which has flooded e-commerce channels with cheap, licensed massagers, forcing SKG to outsource 66.1% of its volume to match competitor pricing.

• Moderna has moved into a very different phase of its post-pandemic story.
• Its shares surged after the Phase 3 INTerpath-001 melanoma study delivered a positive result for intismeran autogene, the individualized mRNA cancer therapy being developed with Merck and used alongside Keytruda.
• The study met its primary recurrence-free-survival endpoint and also succeeded on distant-metastasis-free survival in 1,137 patients with resected high-risk melanoma.

• Novo Nordisk AS reported steady progress during the second quarter of 2026, reflecting ongoing strategic initiatives across its obesity and diabetes franchises, pipeline development, and operational transformation.
• The company now serves over 46 million patients living with obesity and diabetes, representing a nearly 70% increase in obesity treatment patients year-over-year, with nearly 5 million on obesity treatments.
• A key commercial highlight was the global rollout of the Wegovy Pill, which reached approximately 1.5 million users worldwide.

• Inspire Medical Systems reported second quarter 2026 results that were largely impacted by ongoing coding and reimbursement challenges, although some operational areas showed improvement.
• The company’s revenue declined 7.6% year-over-year to $200.6 million, a downturn driven primarily by disruptions in prior authorization processes and uncertainties in billing codes.
• Despite the revenue decline, Inspire managed to deliver adjusted operating income and positive cash flow ahead of expectations through disciplined cost management and a favorable product mix shift toward Inspire V systems.

• IDEXX Laboratories reported solid financial results for the second quarter of 2026, continuing revenue growth driven primarily by its Companion Animal Group (CAG) Diagnostics segment.
• Total revenue increased approximately 10% as reported and 9% organically, led by over 10% organic growth in CAG Diagnostics recurring revenues.
• Growth was complemented by double-digit gains in both domestic and international markets, strong performances in the Water and Livestock, Poultry and Dairy (LPD) businesses, and ongoing expansion in software and diagnostic imaging.